SLC5A2 and hydrops fetalis: A recently published meta-analysis of the large HF outcome trials summarized in Table 3 confirms that SGLT2 inhibitor therapy reduces the risk of cardiovascular death and HF hospitalization in a broad range of patients with HF.32 Based on their findings, the authors concluded that current evidence supports the foundational use of SGLT2 inhibitors to manage HF, irrespective of ejection fraction or care setting.32